Harbour Investments’s Franklin Genomic Advancements ETF HELX Stock Holding History

Harbour Investments’s Portfolio HELX Stock Details HELX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50.1K	Sell	1,255 -395	-24%	-$13.7K	﹤0.01%	2394
2026 Q1	$54.6K	Buy	1,650 +138	+9%	+$4.81K	﹤0.01%	2297
2025 Q4	$54.9K	Sell	1,512 -125	-8%	-$4.41K	﹤0.01%	1923
2025 Q3	$49.9K	Sell	1,637 -50	-3%	-$1.46K	﹤0.01%	1911
2025 Q2	$46.6K	Sell	1,687 -136	-7%	-$3.6K	﹤0.01%	1868
2025 Q1	$49.2K	Buy	1,823 +1,687	+1,240%	+$49.6K	﹤0.01%	1777
2024 Q4	$3.92K	Buy	+136	New	+$4.17K	﹤0.01%	2821
2024 Q3	–	Sell	-188	Closed	-$5.96K	–	3435
2024 Q2	$5.96K	Hold	188	–	–	﹤0.01%	2448
2024 Q1	$6.16K	Hold	188	–	–	﹤0.01%	2397
2023 Q4	$5.73K	Hold	188	–	–	﹤0.01%	2363
2023 Q3	$5.33K	Hold	188	–	–	﹤0.01%	2249
2023 Q2	$5.68K	Hold	188	–	–	﹤0.01%	2238
2023 Q1	$5.71K	Hold	188	–	–	﹤0.01%	2226
2022 Q4	$5.66K	Hold	188	–	–	﹤0.01%	2177
2022 Q3	$6K	Hold	188	–	–	﹤0.01%	2108
2022 Q2	$6K	Buy	+188	New	+$6.2K	﹤0.01%	2108
2021 Q4	$9K	Sell	188 -3,261	-95%	-$163K	﹤0.01%	1970
2021 Q3	$180K	Hold	3,449	–	–	0.01%	1073
2021 Q2	$179K	Hold	3,449	–	–	0.01%	1104
2021 Q1	$150K	Buy	+3,449	New	+$161K	0.01%	1104

Other funds holding HELX

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Harbour Investments's HELX Position: Q2 2026 in Review

Harbour Investments reduced its Franklin Genomic Advancements ETF (HELX) stake by 24% in Q2 2026, selling an estimated $13.7K and leaving 1,255 shares worth $50.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2394.

Harbour Investments first reported a position in HELX in Q1 2021 and has held it in 20 quarters since. The position peaked at $180K in Q3 2021. 6 funds tracked by Wall St. Rank hold HELX as of Q2 2026.

Harbour Investments held 1,255 shares of Franklin Genomic Advancements ETF worth $50.1K as of Q2 2026.
Harbour Investments sold 395 Franklin Genomic Advancements ETF shares in Q2 2026, an estimated $13.7K.
Franklin Genomic Advancements ETF made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #2394 holding.
Harbour Investments first reported a position in Franklin Genomic Advancements ETF in Q1 2021 and has held it in 20 quarters since.
Harbour Investments's Franklin Genomic Advancements ETF position peaked at $180K in Q3 2021.
6 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.